Stryker Co. (NYSE:SYK) VP M Kathryn Fink Sells 7,347 Shares of Stock

Stryker Co. (NYSE:SYK) VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

M Kathryn Fink also recently made the following trade(s):

• On Friday, September 13th, M Kathryn Fink sold 2,121 shares of Stryker stock. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00.

Stryker Trading Down 2.1 %

SYK opened at $364.00 on Wednesday. The business has a fifty day moving average price of $343.60 and a 200 day moving average price of $342.61. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $374.63. The stock has a market capitalization of $138.71 billion, a price-to-earnings ratio of 41.55, a PEG ratio of 2.87 and a beta of 0.91.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. The business had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.54 earnings per share. Sell-side analysts expect that Stryker Co. will post 12 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a $0.80 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s payout ratio is 36.53%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several analyst reports. Barclays lifted their price target on shares of Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $386.00 price target on shares of Stryker in a research note on Wednesday, July 31st. Wolfe Research began coverage on Stryker in a research report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $380.00 target price on shares of Stryker in a research note on Tuesday, September 10th. Finally, Truist Financial dropped their price target on shares of Stryker from $364.00 to $345.00 and set a “hold” rating for the company in a research report on Thursday, August 1st. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $378.58.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently modified their holdings of the company. Burkett Financial Services LLC purchased a new stake in Stryker during the 4th quarter worth about $25,000. Centennial Bank AR lifted its stake in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the last quarter. Central Pacific Bank Trust Division acquired a new position in Stryker in the first quarter valued at approximately $39,000. DSM Capital Partners LLC purchased a new position in Stryker in the fourth quarter valued at approximately $34,000. Finally, Accent Capital Management LLC acquired a new stake in Stryker during the fourth quarter worth approximately $60,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.